Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00263783
Status:
COMPLETED
Last Update Posted:
2009-01-29
First Post:
2005-12-08
Brief Title:
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the safety profile of single and multiple doses of MEDI522 in patients with refractory solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None